| Randomized Pilot Study of Nicotine for "Hunger Pain" in Patients With Malignant Bowel Obstruction Due to Incurable Cancer
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
Nicotine in Treating "Hunger Pain" in Patients With Malignant Bowel Obstruction Caused By Cancer
Basic Trial Information
| Phase | Type | Status | Age | Protocol IDs |
|---|
| No phase specified | Supportive care | Closed | 18 and over | MAYO-MC03C2 NCT00425906 |
Objectives - Determine whether patients with malignant bowel obstruction due to incurable cancer utilize a potential therapy for "hunger pain."
- Determine, preliminarily, the efficacy and toxicity of nicotine in treating "hunger pain" in these patients.
- Determine whether nicotine results in a decline in circulating ghrelin (for patients enrolled at the Mayo Rochester Clinic only).
- Evaluate hormonal changes in patients treated with nicotine (for patients enrolled at the Mayo Rochester Clinic only).
Entry Criteria Disease Characteristics:
- Diagnosis of any incurable malignancy
- Presence of malignant bowel obstruction
- Must be on strict "nothing per os" (NPO) status over the next 48 hours
- Acknowledges that "hunger pain" is a problem
Prior/Concurrent Therapy:
- Concurrent short-term use of dexamethasone or other hormonal therapy or symptom control strategy allowed
Patient Characteristics:
- Mentally competent
- No history of life-threatening arrhythmia
- No severe or worsening angina
- No accelerated hypertension
- No known hypersensitivity to nicotine
- Not pregnant or nursing
- Negative pregnancy test
Expected Enrollment 20A total of 20 patients will be accrued for this study. Outcomes Primary Outcome(s)Determination of whether ≥ 50% of patients utilize nicotine for treating "hunger pain" ≥ 2 times over a 48-hour period
Secondary Outcome(s)Toxicity as measured by CTCAE v 2.0 Global quality of life Hunger assessment Change in circulating hormonal concentrations (for patients enrolled at the Mayo Rochester Clinic only)
Outline This is a randomized, double-blind, placebo-controlled, multicenter, pilot study. Patients are stratified according to vomiting status within the past 24 hours (yes vs no) and use of narcotics (yes vs no). Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive a nicotine inhaler to use as needed for "hunger pain." Treatment continues for up to 48 hours in the absence of unacceptable toxicity .
- Arm II: Patients receive a placebo inhaler to use as needed for "hunger pain." Treatment continues for up to 48 hours in the absence of unacceptable toxicity.
After 48 hours, patients in arm I may continue nicotine therapy off study. Patients in arm II who are not surgical candidates may cross over to treatment with the nicotine inhaler off study. Blood and spot urine samples are collected at baseline and after 48 hours from patients enrolled at the Mayo Rochester Clinic. Blood samples are analyzed to evaluate circulating hormone (e.g., ghrelin, leptin) concentrations. Urine samples are analyzed to evaluate nicotine and nicotine metabolite concentrations. Global quality of life is assessed at baseline and after 48 hours. "Hunger pain" is assessed at baseline.
Trial Contact Information
Trial Lead Organizations Mayo Clinic Cancer Center  |  |  | | Aminah Jatoi, MD, Protocol chair |  | |  | | Gerardo Colon-Otero, MD, Protocol co-chair |  | |  | | Lynn Hartmann, MD, Protocol co-chair |  | |  | | Bobbie Gostout, MD, Protocol co-chair |  | |  | | Richard Hurt, MD, Protocol co-chair |  | |  | | Lorraine Fitzpatrick, MD, Protocol co-chair |  | |  | | Tom Moyer, PhD, Protocol co-chair |  | |  |
| Registry Information |  | | Official Title | | A Pilot Study of Nicotine for "Hunger Pain" in Patients with Bowel Obstruction from Incurable Cancer |  | | Trial Start Date | | 2003-12-15 |  | | Registered in ClinicalTrials.gov | | NCT00425906 |  | | Date Submitted to PDQ | | 2006-11-30 |  | | Information Last Verified | | 2007-06-05 |  | | NCI Grant/Contract Number | | CA15083 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |